Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 31 12 2018
accepted: 27 05 2019
pubmed: 7 6 2019
medline: 18 3 2020
entrez: 8 6 2019
Statut: ppublish

Résumé

Epidemiologic studies that investigated alcohol consumption in relation to the risk of bladder cancer (BCa) have demonstrated inconsistent results. We conducted a systematic review and meta-analysis of the literature to investigate the association of alcohol including different types of alcoholic beverages consumption with the risk of BCa. A systematic search of Web of Science, Medline/PubMed and Cochrane library was performed in May 2018. Studies were considered eligible if they assessed the risk of BCa due to alcohol consumption (moderate or heavy dose) and different types of alcoholic beverages (moderate or heavy dose) in multivariable analysis in the general population (all genders, males or females) or compared with a control group of individuals without BCa. observational cohorts or case-control. Sixteen studies were included in this meta-analysis. Moderate and heavy alcohol consumption did not increase the risk of BCa in the entire population. Sub-group and sensitivity analyses revealed that heavy alcohol consumption increased significantly the risk of BCa in the Japanese population, RR 1.31 (95% CI 1.08-1.58, P < 0.01) in the multivariable analysis, and in males RR of 1.50 (95% CI 1.18-1.92, P < 0.01), with no significant statistical heterogeneity. Moreover, heavy consumption of spirits drinks increased the risk of BCa in males, RR 1.42 (95% CI 1.15-1.75, P < 0.01). In this meta-analysis, moderate and heavy alcohol consumption did not increase the risk of bladder cancer significantly. However, heavy consumption of alcohol might increase the risk of BCa in males and in some specific populations.

Sections du résumé

BACKGROUND BACKGROUND
Epidemiologic studies that investigated alcohol consumption in relation to the risk of bladder cancer (BCa) have demonstrated inconsistent results. We conducted a systematic review and meta-analysis of the literature to investigate the association of alcohol including different types of alcoholic beverages consumption with the risk of BCa.
MATERIALS AND METHODS METHODS
A systematic search of Web of Science, Medline/PubMed and Cochrane library was performed in May 2018. Studies were considered eligible if they assessed the risk of BCa due to alcohol consumption (moderate or heavy dose) and different types of alcoholic beverages (moderate or heavy dose) in multivariable analysis in the general population (all genders, males or females) or compared with a control group of individuals without BCa.
STUDY DESIGN METHODS
observational cohorts or case-control.
RESULTS RESULTS
Sixteen studies were included in this meta-analysis. Moderate and heavy alcohol consumption did not increase the risk of BCa in the entire population. Sub-group and sensitivity analyses revealed that heavy alcohol consumption increased significantly the risk of BCa in the Japanese population, RR 1.31 (95% CI 1.08-1.58, P < 0.01) in the multivariable analysis, and in males RR of 1.50 (95% CI 1.18-1.92, P < 0.01), with no significant statistical heterogeneity. Moreover, heavy consumption of spirits drinks increased the risk of BCa in males, RR 1.42 (95% CI 1.15-1.75, P < 0.01).
CONCLUSION CONCLUSIONS
In this meta-analysis, moderate and heavy alcohol consumption did not increase the risk of bladder cancer significantly. However, heavy consumption of alcohol might increase the risk of BCa in males and in some specific populations.

Identifiants

pubmed: 31172281
doi: 10.1007/s00345-019-02825-4
pii: 10.1007/s00345-019-02825-4
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2313-2324

Références

Int J Epidemiol. 1982 Sep;11(3):212-7
pubmed: 7129735
J Clin Epidemiol. 2002 Jul;55(7):637-41
pubmed: 12160910
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Scand J Urol Nephrol. 1983;17(3):307-12
pubmed: 6689086
Gastroenterology. 2015 Dec;149(7):1700-15
pubmed: 26376349
Lancet Oncol. 2009 Nov;10(11):1033-4
pubmed: 19891056
Prostate. 1993;22(3):253-64
pubmed: 7683816
Cancer. 1988 Jan 15;61(2):402-8
pubmed: 3334975
Int J Urol. 2004 Jan;11(1):11-9
pubmed: 14678179
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BJU Int. 2013 Apr;111(4):589-95
pubmed: 22642265
Hinyokika Kiyo. 1995 Dec;41(12):969-77
pubmed: 8578986
J Natl Cancer Inst. 2004 Sep 15;96(18):1397-400
pubmed: 15367573
Eur J Epidemiol. 1987 Dec;3(4):365-9
pubmed: 3691746
Int J Cancer. 2007 Aug 15;121(4):839-45
pubmed: 17440923
J Natl Cancer Inst. 2009 Mar 4;101(5):296-305
pubmed: 19244173
BMJ. 2014 Jan 24;348:f7450
pubmed: 24464277
Curr Opin Urol. 2018 Jan;28(1):88-92
pubmed: 29211694
Am J Public Health. 1987 Oct;77(10):1298-300
pubmed: 3631363
Eur Urol Focus. 2015 Aug;1(1):17-27
pubmed: 28723350
Am J Epidemiol. 1983 Nov;118(5):720-7
pubmed: 6637998
Int J Cancer. 2001 Sep;93(6):880-7
pubmed: 11519052
Am J Epidemiol. 2001 Jan 1;153(1):38-41
pubmed: 11159145
Tohoku J Exp Med. 2016;239(1):9-15
pubmed: 27098227
Urology. 1999 Nov;54(5):823-8
pubmed: 10565741
Int J Cancer. 2017 Dec 15;141(12):2480-2488
pubmed: 28875523
Am J Epidemiol. 1989 Dec;130(6):1159-63
pubmed: 2589309
Cancer. 1992 Apr 1;69(7):1776-90
pubmed: 1551063
Ann Oncol. 2012 Jun;23(6):1586-93
pubmed: 22039083
Eur Urol. 2013 Apr;63(4):724-32
pubmed: 22925575
Eur J Epidemiol. 1997 Oct;13(7):795-800
pubmed: 9384269
Minerva Urol Nefrol. 2016 Aug;68(4):381-95
pubmed: 27124417
Am J Epidemiol. 1988 Jun;127(6):1179-91
pubmed: 3369417
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Carcinogenesis. 1981;2(4):343-7
pubmed: 7273315
Int J Cancer. 2017 Nov 15;141(10):1963-1970
pubmed: 28722206
Eur Urol. 2016 Feb;69(2):300-10
pubmed: 26346676
Eur J Nutr. 2020 Feb;59(1):287-296
pubmed: 30737562
Nutr Cancer. 1997;29(2):163-8
pubmed: 9427981
Cancer Detect Prev. 2009;32(5-6):352-62
pubmed: 19588541
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Nature. 2016 Sep 14;537(7620):S103-4
pubmed: 27626777
Int Urol Nephrol. 2008;40(3):643-7
pubmed: 18247151
Nat Rev Urol. 2015 Oct;12(10):585-92
pubmed: 26436686
Cancer Epidemiol. 2017 Jun;48:36-40
pubmed: 28364670
Cancer. 2005 Dec 1;104(11):2400-8
pubmed: 16240451
Carcinogenesis. 2016 Jun;37(6):583-588
pubmed: 26992901
Curr Opin Urol. 2018 Jan;28(1):80-87
pubmed: 28984720
J Natl Cancer Inst. 1980 Apr;64(4):701-13
pubmed: 6928984
Cancer Causes Control. 1994 Jul;5(4):326-32
pubmed: 8080944
Am J Epidemiol. 1991 Feb 1;133(3):230-9
pubmed: 2000840
Eur Urol. 2015 Nov;68(5):868-79
pubmed: 26188393
Eur J Epidemiol. 1999 May;15(5):411-9
pubmed: 10442466

Auteurs

Mihai Dorin Vartolomei (MD)

Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Cell and Molecular Biology, University of Medicine, Pharmacy, Sciences and Technology, Targu Mures, Romania.

Takehiro Iwata (T)

Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Beat Roth (B)

Department of Urology, University of Bern, Bern, Switzerland.

Shoji Kimura (S)

Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, Jikei University School of Medicine, Tokyo, Japan.

Romain Mathieu (R)

Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, Rennes University Hospital, Rennes, France.

Matteo Ferro (M)

Division of Urology, European Institute of Oncology, Milan, Italy.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at.
Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at.
Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at.

Christian Seitz (C)

Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH